Messenger Ribonucleic Acid (mRNA) And Next-Generation Vaccine Platforms Market Report 2026

Messenger Ribonucleic Acid (mRNA) And Next-Generation Vaccine Platforms Market Overview

• Messenger Ribonucleic Acid (mRNA) And Next-Generation Vaccine Platforms market size has reached to $39.69 billion in 2025 • Expected to grow to $82.61 billion in 2030 at a compound annual growth rate (CAGR) of 15.8% • Growth Driver: Increasing Demand For Personalized Medicine Is Fueling The Growth Of The Market Due To Rising Adoption Of Precision Therapies • Market Trend: Advancements In mRNA And Next-Generation Vaccine Platforms Strengthen COVID-19 Immunization Strategies • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Messenger Ribonucleic Acid (mRNA) And Next-Generation Vaccine Platforms Market?

Messenger ribonucleic acid (mRNA) and next-generation vaccine platforms refer to advanced vaccine technologies that use genetic instructions, such as mRNA, DNA, or viral vectors, to stimulate the body’s immune system to produce protective proteins and generate immunity against diseases. These platforms enable faster vaccine development, high adaptability to emerging pathogens, scalable manufacturing, and improved immune responses compared to traditional vaccine approaches. The main vaccine types of messenger ribonucleic acid (mRNA) and next-generation vaccine platforms include messenger ribonucleic acid Vaccines, deoxyribonucleic acid (DNA) vaccines, viral vector vaccines, protein subunit vaccines, peptide vaccines, and other vaccine types. Messenger ribonucleic acid (mRNA) vaccines refer to vaccines that use synthetic mRNA sequences to instruct cells to produce specific antigens, thereby triggering an immune response against a target pathogen or disease. These platforms use technologies such as lipid nanoparticle (LNP) delivery, self-amplifying messenger ribonucleic acid (saRNA), circular messenger ribonucleic acid (circRNA), replicon or non-replicating platforms, and viral vector technologies. They are applied for disease indications including infectious diseases, oncology, rare diseases, and other disease indications, and are used by end users including pharmaceutical and biotechnology companies, contract research organizations (CROs), academic and research institutes, and hospitals and clinics.

What Is The Messenger Ribonucleic Acid (mRNA) And Next-Generation Vaccine Platforms Market Growth Forecast?

The messenger ribonucleic acid (mrna) and next-generation vaccine platforms market size is expected to see rapid growth in the next few years. It will grow to $82.61 billion in 2030 at a compound annual growth rate (CAGR) of 15.8%. The growth in the forecast period can be attributed to growth of personalized cancer vaccines, expansion of infectious disease pipelines, faster platform based approvals, increased biotech funding, broader therapeutic vaccine use. Major trends in the forecast period include self amplifying mrna platforms, lipid nanoparticle delivery optimization, modular vaccine platform design, rapid pathogen target adaptation, next generation adjuvant systems.

Global Messenger Ribonucleic Acid (mRNA) And Next-Generation Vaccine Platforms Market Segmentation

1) By Vaccine Type: Messenger Ribonucleic Acid Vaccines; Deoxyribonucleic Acid (DNA) Vaccines; Viral Vector Vaccines; Protein Subunit Vaccines; Peptide Vaccines; Other Vaccine Types 2) By Technology or Platform: Lipid Nanoparticle (LNP) Delivery; Self-Amplifying Messenger Ribonucleic Acid; Circular Messenger Ribonucleic Acid; Replicon or Non-replicating Platforms; Viral Vector Technologies 3) By Disease Indication: Infectious Diseases; Oncology; Rare Diseases; Other Disease Indications 4) By End User: Pharmaceutical and Biotechnology Companies; Contract Research Organizations (CROs); Academic and Research Institutes; Hospitals and Clinics Subsegments: 1) By Messenger Ribonucleic Acid Vaccines: Conventional Messenger Ribonucleic Acid Vaccines; Self Amplifying Messenger Ribonucleic Acid Vaccines; Modified Messenger Ribonucleic Acid Vaccines; Circular Messenger Ribonucleic Acid Vaccines 2) By Deoxyribonucleic Acid Vaccines: Plasmid Deoxyribonucleic Acid Vaccines; Viral Assisted Deoxyribonucleic Acid Vaccines; Synthetic Deoxyribonucleic Acid Vaccines; Gene Based Deoxyribonucleic Acid Vaccines 3) By Viral Vector Vaccines: Adenovirus Based Viral Vector Vaccines; Lentivirus Based Viral Vector Vaccines; Poxvirus Based Viral Vector Vaccines; Measles Virus Based Viral Vector Vaccines 4) By Protein Subunit Vaccines: Recombinant Protein Vaccines; Virus Like Particle Vaccines; Toxoid Based Protein Vaccines; Polysaccharide Conjugate Vaccines 5) By Peptide Vaccines: Synthetic Peptide Vaccines; Personalized Peptide Vaccines; Multi Epitope Peptide Vaccines; Long Peptide Vaccines 6) By Other Vaccine Types: Protein Subunit Vaccines, Virus-Like Particle Vaccines, Inactivated Vaccines, Live Attenuated Vaccines, Recombinant Vector Vaccines

What Is The Driver Of The Messenger Ribonucleic Acid (mRNA) And Next-Generation Vaccine Platforms Market?

The increasing demand for personalized medicine is expected to propel the growth of the messenger ribonucleic acid (mRNA) and next-generation vaccine platforms market going forward. Personalized medicine is a medical approach in which disease prevention and treatment strategies are tailored based on an individual’s genetic profile, molecular characteristics, and specific health conditions. The rise in demand for personalized medicine is due to the growing prevalence of complex and chronic diseases, as these conditions require targeted and patient-specific therapeutic solutions to improve treatment efficacy and safety outcomes. Messenger ribonucleic acid (mRNA) and next-generation vaccine platforms support personalized medicine by enabling rapid, flexible, and highly specific vaccine and therapeutic designs that can be customized to individual genetic and disease profiles, supporting precision-based healthcare delivery. For instance, in February 2024, according to the Personalized Medicine Coalition, a US-based hospital and health care organization, in 2023, the FDA approved 16 new personalized treatments for rare disease patients, up from six in 2022. Therefore, the increasing demand for personalized medicine is driving the growth of the messenger ribonucleic acid (mRNA) and next-generation vaccine platforms industry.

Key Players In The Global Messenger Ribonucleic Acid (mRNA) And Next-Generation Vaccine Platforms Market

Major companies operating in the messenger ribonucleic acid (mrna) and next-generation vaccine platforms market are Pfizer Inc., Sanofi S.A., AstraZeneca PLC, Thermo Fisher Scientific Inc., GSK plc, Takeda Pharmaceutical Company Limited, Daiichi Sankyo Company Limited, Moderna Inc., BioNTech SE, Novavax Inc., Walvax Biotechnology Co Ltd, Arcturus Therapeutics Inc, Gennova Biopharmaceuticals Ltd, Vaxxas Pty Ltd, Vaxart Inc, Ethris GmbH, The Biologicals and Vaccines Institute of Southern Africa Proprietary Limited, eTheRNA Immunotherapies NV, Stemirna Therapeutics Co Ltd, Primrose Bio Inc, Acuitas Therapeutics Inc, and Incepta Vaccine Ltd.

Global Messenger Ribonucleic Acid (mRNA) And Next-Generation Vaccine Platforms Market Trends and Insights

Major companies operating in the mRNA and next-generation vaccine platforms market are focusing on developing next-generation mRNA-based COVID-19 vaccines to enhance immune durability, broaden variant coverage, and improve overall vaccine performance. Next-generation mRNA-based COVID-19 vaccines leverage improved mRNA engineering and delivery technologies to provide broader and more durable protection against existing and emerging SARS-CoV-2 variants and enhance safety, stability, and storage convenience while allowing rapid adaptation to viral evolution. For instance, in June 2025, Moderna Inc., a US-based biotechnology company, introduced mNEXSPIKE, its next-generation COVID-19 vaccine designed to improve protection against circulating and emerging SARS-CoV-2 variants. The vaccine incorporates an updated spike protein antigen that more closely matches recent variants and aims to deliver enhanced immune durability and effectiveness, supporting ongoing COVID-19 prevention efforts and future booster strategies.

What Are Latest Mergers And Acquisitions In The Messenger Ribonucleic Acid (mRNA) And Next-Generation Vaccine Platforms Market?

In July 2024, GlaxoSmithKline plc, a UK-based pharmaceutical and biotechnology company, partnered with CureVac N.V. to advance next-generation mRNA vaccines and accelerate development. The partnership aims to fortify GlaxoSmithKline's vaccine pipeline by gaining strategic control over next-generation mRNA programs and expediting their development and commercialization. CureVac N.V. is a Germany-based biotechnology company that specializes in next-generation messenger ribonucleic acid-based Covid and flu vaccines.

Regional Insights

North America was the largest region in the messenger ribonucleic acid (mRNA) and next-generation vaccine platforms market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Messenger Ribonucleic Acid (mRNA) And Next-Generation Vaccine Platforms Market?

The messenger ribonucleic acid (mRNA) and next-generation vaccine platforms market includes sales of messenger ribonucleic acid vaccines, lipid nanoparticle delivery systems, viral vector vaccines, protein subunit vaccines, recombinant antigen vaccines, next-generation adjuvants, synthetic ribonucleic acid constructs, stabilized messenger ribonucleic acid formulations, immune response modulators, and nucleic acid-based vaccine platforms. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Messenger Ribonucleic Acid (mRNA) And Next-Generation Vaccine Platforms Market Report 2026?

The messenger ribonucleic acid (mrna) and next-generation vaccine platforms market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the messenger ribonucleic acid (mrna) and next-generation vaccine platforms industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.